GSE210476 rutaecarpine macrophage 11 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE210476_rutaecarpine_macrophage_11_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE210476_rutaecarpine_macrophage_11_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE210476_rutaecarpine_macrophage_11_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE210476_rutaecarpine_macrophage_11_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

TPTE pseudogene 1

Gene

long intergenic non-protein coding RNA 865

Gene

long intergenic non-protein coding RNA 1270

Gene

uncharacterized LOC105374901

Gene

GLYATL1 antisense RNA 1

Gene

TTC12 divergent transcript

Gene

uncharacterized LOC105371240

Gene

long intergenic non-protein coding RNA 1102

Gene

uncharacterized LOC101928844

Gene

STAT4 antisense RNA 1

  • Gene

    TPTE pseudogene 1


  • Gene

    long intergenic non-protein coding RNA 865


  • Gene

    long intergenic non-protein coding RNA 1270


  • Gene

    uncharacterized LOC105374901


  • Gene

    GLYATL1 antisense RNA 1


  • Gene

    TTC12 divergent transcript


  • Gene

    uncharacterized LOC105371240


  • Gene

    long intergenic non-protein coding RNA 1102


  • Gene

    uncharacterized LOC101928844


  • Gene

    STAT4 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.